Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 1997

View Archived Issues

Yamanouchi's overseas R&D pipeline

R&D at Mitsui Pharmaceuticals

Immunomedics granted Japanese patent for cancer diagnostic technology

Initial clinical results with LGD-1069

Combination of immunosuppression and rhIL-3 for aplastic anemia

AIDS progression and link to chemokine receptors

Sequus seeks FDA approval for new indication of Amphotec

NMDA antagonists claimed by Novartis

Akzo Nobel reveals new dopamine antagonists

Substance P antagonists described by Pfizer

Knoll claims two series of compounds for CNS disorders

Protein tyrosine kinase inhibitors from Glaxo Wellcome

Selective cGMP-PDE inhibitors claimed by Otsuka

The Rockefeller University develops OCD marker

Beth Israel evaluates bFGF for coronary artery disease

Montelukast associated wth bronchodilating effects in asthmatics

Bronchodilating effect of furosemide not secondary to prostaglandin release

First approval for Zomig; antimigraine agents in development

MP-52 enters clinic

Anticancer agent from Banyu heading for clinic

NM-702 enters phase II trials

Therics receives SBIR grant for ocular drug delivery R&D

MGI Pharma and Schein reach marketing agreement for INFeD

Astra Merck launches Lexxel in U.S.

MRC, Sankyo and Oncogene Science to develop new antiflu drugs

BBI Pharmaceuticals to fund phase I trial with soybean extract in BPH

NanoSystems and Astra Draco collaborate for respiratory disorders

Water-soluble HIV protease inhibitor from Sankyo

Advanced Viral Research and the NCI sign genetic research agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...